+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anthrax Treatment Market - Global Forecast 2026-2032- Product Image
Anthrax Treatment Market - Global Forecast 2026-2032- Product Image
New

Anthrax Treatment Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 199 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6015073
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Anthrax treatment preparedness demands a coordinated, evidence-based strategy, spanning clinical advancements, policy frameworks, and supply chain resilience. As risks remain from both naturally occurring outbreaks and potential deliberate incidents, senior decision-makers must focus on safeguarding access to therapeutics and ensuring operational readiness throughout the healthcare ecosystem.

Market Snapshot: Anthrax Treatment Market Growth and Outlook

The Anthrax Treatment Market grew from USD 449.92 million in 2025 to USD 488.90 million in 2026. It is expected to continue growing at a CAGR of 8.12%, reaching USD 777.55 million by 2032. This robust trajectory reflects greater investments in biodefense, evolving regulatory policies, and a renewed emphasis on regional manufacturing capacity. Market drivers include advances in biologics, ongoing vaccine innovation, and adjustments to procurement strategy resulting from shifting global trade environments.

Scope & Segmentation

  • Therapeutic Modalities: Antibiotics (ciprofloxacin, doxycycline, penicillin), monoclonal antitoxins, and a range of supportive care interventions remain central to both acute and prophylactic management.
  • Vaccines and Technology Platforms: Vaccine approaches extend from adsorbed whole-cell preparations to new recombinant protective antigen constructs, supporting both pre- and post-exposure protocols.
  • End Users: Key stakeholders include hospitals, clinics, public health agencies, and research institutes, each shaping procurement priorities and influencing response logistics.
  • Distribution Pathways: Product availability hinges on government procurement, hospital pharmacies, retail channels, and select online dispensaries, each requiring tailored distribution strategies.
  • Routes of Administration: Options span intravenous and oral delivery, optimizing for both systemic severe cases and broad community deployment.
  • Regional Focus: Market dynamics differ in the Americas, Europe, Middle East & Africa, and Asia-Pacific, shaped by local manufacturing capabilities and public health infrastructure.

Key Takeaways for Decision-Makers

  • Recent technological advances, including monoclonal antitoxins and recombinant vaccine platforms, are elevating clinical treatment standards and stockpiling efficacy.
  • Procurement strategy is increasingly shaped by resilience imperatives, with emphasis placed on domestic manufacturing and supply chain diversification to address vulnerabilities.
  • Clinical protocols now prioritize not just first-line antibiotics but also real-time monitoring for resistance trends and adaptive approaches during supply disruptions.
  • Regional heterogeneity in infrastructure and public-private sector engagement underscores the necessity for tailored readiness and distribution plans.
  • Collaborations between commercial developers and government agencies are critical to synchronized emergency authorizations, scaling of manufacturing, and effective deployment during crises.
  • Integrated planning that brings together clinical leadership, procurement, and regulatory affairs is essential to successfully navigate both predictable and emergent challenges in anthrax response.

Anthrax Treatment Market: Tariff Impact and Supply Chain Resilience

Tariff measures introduced in 2025 have shaped the landscape of supply chain operations. Heightened tariffs on pharmaceutical intermediates and biologics have led to increased costs and delays in sourcing essential materials. Senior decision-makers at manufacturing and procurement agencies have responded by diversifying supplier portfolios, shoring up domestic production, and embedding contingency clauses into contracts. Hospital systems, in turn, have adapted clinical protocols to manage temporary scarcity, prioritizing critical therapies while sustaining overall readiness. This experience highlights the close interdependency between international trade policy and national health system preparedness.

Methodology & Data Sources

This analysis blends qualitative interviews with clinicians, procurement officers, and manufacturing leaders with a structured review of public clinical guidance, regulatory announcements, and manufacturing reports. All findings are triangulated with input from subject matter experts and validated through cross-reference with current technical and policy literature for accuracy and actionable relevance.

Why This Report Matters

  • Enables strategic planning by mapping clinical advances, supply chain risks, and procurement best practices for leaders navigating complex anthrax threats.
  • Offers segmented intelligence on therapeutic, operational, and regional priorities to support investment, resource allocation, and emergency preparedness decisions.
  • Clarifies the implications of regulatory and trade shifts, empowering organizations to respond adaptively to market evolution and disruption.

Conclusion

Achieving and sustaining anthrax treatment readiness relies on a holistic approach that unites clinical innovation, resilient operations, and forward-looking procurement. Integrated strategies ensure that therapeutic advances translate into meaningful public health protection and operational continuity.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Anthrax Treatment Market, by Therapeutic Modality
8.1. Antibiotic Therapy
8.1.1. Ciprofloxacin
8.1.2. Doxycycline
8.1.3. Penicillin
8.2. Antitoxin Therapy
8.2.1. Anthim
8.2.2. Obiltoxaximab
8.2.3. Raxibacumab
8.3. Supportive Care
8.3.1. Intensive Care Treatment
8.3.2. Respiratory Support
8.3.3. Symptomatic Treatment
8.4. Vaccine Therapy
8.4.1. Anthrax Vaccine Adsorbed
8.4.2. Recombinant Protective Antigen Vaccine
9. Anthrax Treatment Market, by Route Of Administration
9.1. Intravenous Administration
9.2. Oral Administration
10. Anthrax Treatment Market, by End User
10.1. Clinics
10.2. Hospitals
10.3. Public Health Agencies
10.4. Research Institutes
11. Anthrax Treatment Market, by Distribution Channel
11.1. Hospital Pharmacies
11.2. Online Pharmacies
11.3. Retail Pharmacies
12. Anthrax Treatment Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Anthrax Treatment Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Anthrax Treatment Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Anthrax Treatment Market
16. China Anthrax Treatment Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Altimmune, Inc.
17.6. AstraZeneca PLC
17.7. Bavarian Nordic A/S
17.8. Bharat Biotech International Limited
17.9. CSL Limited
17.10. Daiichi Sankyo Company, Limited
17.11. Elusys Therapeutics, Inc.
17.12. Emergent BioSolutions Inc.
17.13. GlaxoSmithKline plc
17.14. Humanigen, Inc.
17.15. Johnson & Johnson Services, Inc.
17.16. Lonza Group AG
17.17. Merck & Co., Inc.
17.18. Novartis AG
17.19. Ology Bioservices, Inc.
17.20. Pfenex Inc.
17.21. Pfizer Inc.
17.22. PharmAthene, Inc.
17.23. Sanofi S.A.
17.24. Serum Institute of India Pvt. Ltd.
17.25. Soligenix, Inc.
17.26. Takeda Pharmaceutical Company Limited
List of Figures
FIGURE 1. GLOBAL ANTHRAX TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ANTHRAX TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ANTHRAX TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY THERAPEUTIC MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA ANTHRAX TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ANTHRAX TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTIC THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTIC THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTIC THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY CIPROFLOXACIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY CIPROFLOXACIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY CIPROFLOXACIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY DOXYCYCLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY DOXYCYCLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY DOXYCYCLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY PENICILLIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY PENICILLIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY PENICILLIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXIN THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXIN THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXIN THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXIN THERAPY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ANTHIM, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ANTHIM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ANTHIM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY OBILTOXAXIMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY OBILTOXAXIMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY OBILTOXAXIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY RAXIBACUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY RAXIBACUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY RAXIBACUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY INTENSIVE CARE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY INTENSIVE CARE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY INTENSIVE CARE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY RESPIRATORY SUPPORT, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY RESPIRATORY SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY RESPIRATORY SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY SYMPTOMATIC TREATMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY SYMPTOMATIC TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY SYMPTOMATIC TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY VACCINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY VACCINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY VACCINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY VACCINE THERAPY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ANTHRAX VACCINE ADSORBED, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ANTHRAX VACCINE ADSORBED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ANTHRAX VACCINE ADSORBED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY RECOMBINANT PROTECTIVE ANTIGEN VACCINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY RECOMBINANT PROTECTIVE ANTIGEN VACCINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY RECOMBINANT PROTECTIVE ANTIGEN VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY PUBLIC HEALTH AGENCIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY PUBLIC HEALTH AGENCIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY PUBLIC HEALTH AGENCIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 84. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 85. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 86. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXIN THERAPY, 2018-2032 (USD MILLION)
TABLE 87. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 88. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY VACCINE THERAPY, 2018-2032 (USD MILLION)
TABLE 89. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 90. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 91. AMERICAS ANTHRAX TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 92. NORTH AMERICA ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. NORTH AMERICA ANTHRAX TREATMENT MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 94. NORTH AMERICA ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 95. NORTH AMERICA ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXIN THERAPY, 2018-2032 (USD MILLION)
TABLE 96. NORTH AMERICA ANTHRAX TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 97. NORTH AMERICA ANTHRAX TREATMENT MARKET SIZE, BY VACCINE THERAPY, 2018-2032 (USD MILLION)
TABLE 98. NORTH AMERICA ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 99. NORTH AMERICA ANTHRAX TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 100. NORTH AMERICA ANTHRAX TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 101. LATIN AMERICA ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. LATIN AMERICA ANTHRAX TREATMENT MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 103. LATIN AMERICA ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 104. LATIN AMERICA ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXIN THERAPY, 2018-2032 (USD MILLION)
TABLE 105. LATIN AMERICA ANTHRAX TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 106. LATIN AMERICA ANTHRAX TREATMENT MARKET SIZE, BY VACCINE THERAPY, 2018-2032 (USD MILLION)
TABLE 107. LATIN AMERICA ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 108. LATIN AMERICA ANTHRAX TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 109. LATIN AMERICA ANTHRAX TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXIN THERAPY, 2018-2032 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY VACCINE THERAPY, 2018-2032 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 119. EUROPE ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. EUROPE ANTHRAX TREATMENT MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 121. EUROPE ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 122. EUROPE ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXIN THERAPY, 2018-2032 (USD MILLION)
TABLE 123. EUROPE ANTHRAX TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 124. EUROPE ANTHRAX TREATMENT MARKET SIZE, BY VACCINE THERAPY, 2018-2032 (USD MILLION)
TABLE 125. EUROPE ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 126. EUROPE ANTHRAX TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 127. EUROPE ANTHRAX TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 128. MIDDLE EAST ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. MIDDLE EAST ANTHRAX TREATMENT MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 130. MIDDLE EAST ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 131. MIDDLE EAST ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXIN THERAPY, 2018-2032 (USD MILLION)
TABLE 132. MIDDLE EAST ANTHRAX TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 133. MIDDLE EAST ANTHRAX TREATMENT MARKET SIZE, BY VACCINE THERAPY, 2018-2032 (USD MILLION)
TABLE 134. MIDDLE EAST ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 135. MIDDLE EAST ANTHRAX TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 136. MIDDLE EAST ANTHRAX TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 137. AFRICA ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 138. AFRICA ANTHRAX TREATMENT MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 139. AFRICA ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 140. AFRICA ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXIN THERAPY, 2018-2032 (USD MILLION)
TABLE 141. AFRICA ANTHRAX TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 142. AFRICA ANTHRAX TREATMENT MARKET SIZE, BY VACCINE THERAPY, 2018-2032 (USD MILLION)
TABLE 143. AFRICA ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 144. AFRICA ANTHRAX TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 145. AFRICA ANTHRAX TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXIN THERAPY, 2018-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY VACCINE THERAPY, 2018-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC ANTHRAX TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 155. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 156. ASEAN ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 157. ASEAN ANTHRAX TREATMENT MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 158. ASEAN ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 159. ASEAN ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXIN THERAPY, 2018-2032 (USD MILLION)
TABLE 160. ASEAN ANTHRAX TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 161. ASEAN ANTHRAX TREATMENT MARKET SIZE, BY VACCINE THERAPY, 2018-2032 (USD MILLION)
TABLE 162. ASEAN ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 163. ASEAN ANTHRAX TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 164. ASEAN ANTHRAX TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 165. GCC ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 166. GCC ANTHRAX TREATMENT MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 167. GCC ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 168. GCC ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXIN THERAPY, 2018-2032 (USD MILLION)
TABLE 169. GCC ANTHRAX TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 170. GCC ANTHRAX TREATMENT MARKET SIZE, BY VACCINE THERAPY, 2018-2032 (USD MILLION)
TABLE 171. GCC ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 172. GCC ANTHRAX TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 173. GCC ANTHRAX TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 174. EUROPEAN UNION ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 175. EUROPEAN UNION ANTHRAX TREATMENT MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 176. EUROPEAN UNION ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 177. EUROPEAN UNION ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXIN THERAPY, 2018-2032 (USD MILLION)
TABLE 178. EUROPEAN UNION ANTHRAX TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 179. EUROPEAN UNION ANTHRAX TREATMENT MARKET SIZE, BY VACCINE THERAPY, 2018-2032 (USD MILLION)
TABLE 180. EUROPEAN UNION ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 181. EUROPEAN UNION ANTHRAX TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION ANTHRAX TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 183. BRICS ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 184. BRICS ANTHRAX TREATMENT MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 185. BRICS ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 186. BRICS ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXIN THERAPY, 2018-2032 (USD MILLION)
TABLE 187. BRICS ANTHRAX TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 188. BRICS ANTHRAX TREATMENT MARKET SIZE, BY VACCINE THERAPY, 2018-2032 (USD MILLION)
TABLE 189. BRICS ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 190. BRICS ANTHRAX TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 191. BRICS ANTHRAX TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 192. G7 ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 193. G7 ANTHRAX TREATMENT MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 194. G7 ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 195. G7 ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXIN THERAPY, 2018-2032 (USD MILLION)
TABLE 196. G7 ANTHRAX TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 197. G7 ANTHRAX TREATMENT MARKET SIZE, BY VACCINE THERAPY, 2018-2032 (USD MILLION)
TABLE 198. G7 ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 199. G7 ANTHRAX TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 200. G7 ANTHRAX TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 201. NATO ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 202. NATO ANTHRAX TREATMENT MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 203. NATO ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 204. NATO ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXIN THERAPY, 2018-2032 (USD MILLION)
TABLE 205. NATO ANTHRAX TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 206. NATO ANTHRAX TREATMENT MARKET SIZE, BY VACCINE THERAPY, 2018-2032 (USD MILLION)
TABLE 207. NATO ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 208. NATO ANTHRAX TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 209. NATO ANTHRAX TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 210. GLOBAL ANTHRAX TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 211. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 212. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 213. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 214. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXIN THERAPY, 2018-2032 (USD MILLION)
TABLE 215. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 216. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY VACCINE THERAPY, 2018-2032 (USD MILLION)
TABLE 217. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 218. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 219. UNITED STATES ANTHRAX TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 220. CHINA ANTHRAX TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 221. CHINA ANTHRAX TREATMENT MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
TABLE 222. CHINA ANTHRAX TREATMENT MARKET SIZE, BY ANTIBIOTIC THERAPY, 2018-2032 (USD MILLION)
TABLE 223. CHINA ANTHRAX TREATMENT MARKET SIZE, BY ANTITOXIN THERAPY, 2018-2032 (USD MILLION)
TABLE 224. CHINA ANTHRAX TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
TABLE 225. CHINA ANTHRAX TREATMENT MARKET SIZE, BY VACCINE THERAPY, 2018-2032 (USD MILLION)
TABLE 226. CHINA ANTHRAX TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 227. CHINA ANTHRAX TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 228. CHINA ANTHRAX TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Anthrax Treatment market report include:
  • Altimmune, Inc.
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Bharat Biotech International Limited
  • CSL Limited
  • Daiichi Sankyo Company, Limited
  • Elusys Therapeutics, Inc.
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • Humanigen, Inc.
  • Johnson & Johnson Services, Inc.
  • Lonza Group AG
  • Merck & Co., Inc.
  • Novartis AG
  • Ology Bioservices, Inc.
  • Pfenex Inc.
  • Pfizer Inc.
  • PharmAthene, Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • Soligenix, Inc.
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages199
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 488.9 Million
Forecasted Market Value ( USD ) by 2032 $ 777.55 Million
Compound Annual Growth Rate8.1%
Regions CoveredGlobal
No. of Companies Mentioned23

Related Topics

Related Reports

Anthrax Therapeutics - Global Strategic Business Report - Product Image

Anthrax Therapeutics - Global Strategic Business Report

  • Report
  • 221 Pages
  • Global
From
Anthrax Treatment - Global Strategic Business Report - Product Image

Anthrax Treatment - Global Strategic Business Report

  • Report
  • 373 Pages
  • Global
From
Anthrax - Pipeline Insight, 2025 - Product Image

Anthrax - Pipeline Insight, 2025

  • Clinical Trials
  • 50 Pages
  • Global
From
Anthrasil Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Anthrasil Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From
BAT (Botulism Antitoxin Heptavalent) Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

BAT (Botulism Antitoxin Heptavalent) Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From

About the Anthrax Drug Market

The Anthrax Drug market is a subset of the Infectious Diseases Drugs market, which focuses on the development and sale of drugs to treat and prevent anthrax. Anthrax is a serious bacterial infection caused by the bacterium Bacillus anthracis. It can be contracted through contact with infected animals or contaminated animal products, or through inhalation of the bacteria. Treatment of anthrax typically involves antibiotics, such as ciprofloxacin, doxycycline, and penicillin. Vaccines are also available to prevent anthrax infection. The Anthrax Drug market is highly competitive, with a number of companies offering products to treat and prevent anthrax. These include GlaxoSmithKline, Pfizer, Merck, and Sanofi. Other companies, such as Emergent BioSolutions, are also involved in the development of anthrax drugs. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.